Meta-Analysis of Randomized Trials of Glycoprotein IIb/IIIa Inhibitors in High-Risk Acute Coronary Syndromes Patients Undergoing Invasive Strategy

Study Questions:

What is the comparative effectiveness of a strategy of upstream administration of glycoprotein (GP) IIb/IIIa inhibitors, aimed at cooling the culprit coronary plaque before angioplasty, to a strategy of downstream selective administration of such drugs?